Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prediction Models Of Persistent Taxane-induced Peripheral Neuropathy Among Breast Cancer Survivors Using Whole-exome Sequencing.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prediction Models Of Persistent Taxane-induced Peripheral Neuropathy Among Breast Cancer Survivors Using Whole-exome Sequencing.

Related Experiment Video

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing.

Kristina Engvall1, Hanna Uvdal2, Niclas Björn2

  • 1Department of Oncology, Jönköping, Region Jönköping County, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. kristina.engvall@liu.se.

NPJ Precision Oncology
|May 16, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Polygenic models can predict taxane-induced peripheral neuropathy (TIPN) risk in breast cancer survivors. These models accurately identified survivors with numbness or tingling in their feet, improving quality of life prediction.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.6K

Related Experiment Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.6K

Area of Science:

  • Oncology
  • Genetics
  • Neurology

Background:

  • Persistent taxane-induced peripheral neuropathy (TIPN) significantly impacts early-stage breast cancer survivors' quality of life.
  • Developing predictive models for TIPN is crucial for managing this prevalent side effect.

Purpose of the Study:

  • To develop and validate polygenic prediction models for persistent TIPN symptoms in early-stage breast cancer survivors (ESBCS).
  • To assess the accuracy of these models when incorporating clinical risk factors.

Main Methods:

  • Logistic regression models were used to create and validate polygenic prediction models.
  • Whole-exome sequencing data from 337 ESBCS were analyzed.
  • Models were tested on training and validation cohorts, considering clinical risk factors.

Main Results:

  • Two of five prediction models achieved AUC > 60% for individual PN symptoms.
  • A model for foot numbness (35 SNVs) correctly predicted 73% of survivors.
  • A model for foot tingling (55 SNVs) correctly predicted 70% of survivors.
  • Models identified specific SNVs in genes including ADAMTS20, CYP2C8, and SCN10A.

Conclusions:

  • Polygenic prediction models, incorporating clinical risk factors, can estimate the risk of persistent taxane-induced numbness and tingling in the feet for ESBCS.
  • These models show promise for personalized risk assessment and management of TIPN.